Chimeric Rats for Liver Humanization

Information

  • Research Project
  • 8715278
  • ApplicationId
    8715278
  • Core Project Number
    R43DK105578
  • Full Project Number
    1R43DK105578-01A1
  • Serial Number
    105578
  • FOA Number
    PA-13-234
  • Sub Project Id
  • Project Start Date
    9/30/2014 - 10 years ago
  • Project End Date
    6/30/2015 - 9 years ago
  • Program Officer Name
    DENSMORE, CHRISTINE L
  • Budget Start Date
    9/30/2014 - 10 years ago
  • Budget End Date
    6/30/2015 - 9 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    9/27/2014 - 10 years ago
Organizations

Chimeric Rats for Liver Humanization

DESCRIPTION (provided by applicant): Yecuris has developed an in vivo genetic selection system (the FRG KO mouse) that permits extensive humanization of murine liver by transplantation with human hepatocytes. This model has many potential commercial applications in drug development and testing, both in the in vivo and in vitro markets, .The mouse, however, is a small rodent and therefore the number of human hepatocytes that can be obtained for in vitro studies is limited to 80-150 million hepatocytes/animal. A larger animal that could be similarly repopulated would provide significant cost savings and economy of scale. Furthermore, the rat is the animal model of choice in many preclinical applications, particularly toxicology. For these reasons, we decided to generate an FRG KO rat, with mutations completely analogous to those in the FRG KO mouse: Fumary lacetoacetate hydrolase (Fah), Rag2 and common gamma chain of the interleukin receptor (Il2rg). Using TALEN and other gene editing technologies, strains of rats bearing independent mutations in each of these genes have been generated. The goals of this SBIR are straightforward. We propose to a) generate a colony of triple mutant immune deficient Fah knockout, FRG KO rats, and b) optimize the conditions for hepatocyte transplantation and repopulation in using the single knock out Fah-/- rats. Success with this phase I project will enable the use of FRG KO rats for the assessment of commercial production of human hepatocytes. Aim 1: Intercross of rats bearing mutations in Fah, Rag2 and Il2rg to create a colony of triple mutant FRG KO rats. 1a) Knockout alleles of all three genes have been generated, as well as homozygous Fah-/-/Rag2-/- and Fah-/- /Il2rg-/- rats. Homozygous rats for each mutant will be intercrossed to generate triple heterozygote male and female breeders. These will be crossed to generate a colony of triple mutant FRG KO rats. 1b) Fertility of male and female FRG KO rats will be confirmed. Aim 2: Complete characterization of the FRG KO Analysis of key phenotypes in the FRGKO rats. 2a) the relevant phenotypes of triple mutant FRG KO rats will be characterized. 2b) Untransplanted FRG KO rats will be subjected to different NTBC withdrawal regimens in order to determine the most aggressive regimen compatible with survival. Liver function and histology will be analyzed to determine the extent of liver damage. Aim 3: Optimization of NTBC cycling in FRG KO rats transplanted with GFP-SS rat hepatocytes. 3a) Once the NTBC cycling has been determined, FRG KO rats will be transplanted with Fah+/+ GFP-SS rat hepatocytes, subjected to variations of the most severe NTBC cycling to allow for engraftment and repopulation of the Fah+/+ hepatocytes. The transplanted animals will be harvested for quantification of liver repopulation. Aim 4 Humanization and characterization of the FRG KO rat. 4a) Using the optimized NTBC cycling regime determined in Aim 3, we will transplant human hepatocytes into the FRG KO rats. Engraftment and repopulation will be evaluated by serum levels of human albumin and appropriate correlations established. 4b) Immunohistochemistry analysis will be performed on the liver, spleen and kidneys of the humanized FRG KO rats.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    243211
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:243211\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    YECURIS CORPORATION
  • Organization Department
  • Organization DUNS
    801452249
  • Organization City
    PORTLAND
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    972393098
  • Organization District
    UNITED STATES